Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 4/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | NEK2 | P51955 | 3/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12198441 | 0.86 | ATR (0.52) | ATRNEK2CYP2A6ADKCHEK2 | |
| SCHEMBL6696482 | 0.85 | PIK3CG (0.55) | ATRPIK3CGLTA4HMKNK1MKNK2 | |
| SCHEMBL934795 | 0.79 | ADORA1 (0.56) | ATRPIK3CGPRKDCATMBCHE | |
| SCHEMBL6701889 | 0.79 | ADORA1 (0.56) | ATRPIK3CGPRKDCATMBCHE | |
| SCHEMBL6704802 | 0.77 | PIK3CG (0.51) | ATRPIK3CGNEK2PRKDCATM | |
| SCHEMBL2506344 | 0.76 | ATR (0.47) | ATRNEK2CYP2A6ADKCHEK1 | |
| SCHEMBL934746 | 0.76 | MAPT (0.51) | ATRFYNPIK3CGLTA4HMKNK1 | |
| SCHEMBL2933060 | 0.75 | KCNH2 (0.67) | ATRMKNK1MKNK2CHEK1KCNH2 | |
| SCHEMBL2931488 | 0.74 | NEK2 (0.64) | ATRPIK3CGNEK2PRKDCATM | |
| SCHEMBL2505631 | 0.72 | ROCK1 (0.47) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454261-B1 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | UNIV SIENA (IT) | 2014-11-19 | — | — | EP | disclosed |
| US-8546147-B2 | Imidazo[1,2-α]pyrazin-3(7H)-one derivatives bearing a new electron-rich structure | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2013-10-01 | — | — | US | disclosed |
| US-20120171703-A1 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2012-07-05 | — | — | US | disclosed |
| EP-2454261-A1 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | Universita Degli Studi di Siena (IT) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011007314-A1 | IMIDAZO[1,2-α]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171703-A1 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | GLB1, NDUFV1, IK | ATR 4787/4885FYN 3907/4885PIK3CG 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.